35657956|t|Targeting mitochondrial DNA polymerase gamma for selective inhibition of MLH1 deficient colon cancer growth.
35657956|a|Synthetic lethality in DNA repair pathways is an important strategy for the selective treatment of cancer cells without harming healthy cells and developing cancer-specific drugs. The synthetic lethal interaction between the mismatch repair (MMR) protein, MutL homolog 1 (MLH1), and the mitochondrial base excision repair protein, DNA polymerase gamma (Pol gamma) was used in this study for the selective treatment of MLH1 deficient cancers. Germline mutations in the MLH1 gene and aberrant MLH1 promoter methylation result in an increased risk of developing many cancers, including nonpolyposis colorectal and endometrial cancers. Because the inhibition of Pol gamma in MLH1 deficient cancer cells provides the synthetic lethal selectivity, we conducted a comprehensive small molecule screening from various databases and chemical drug library molecules for novel Pol gamma inhibitors that selectively kill MLH1 deficient cancer cells. We characterized these Pol gamma inhibitor molecules in vitro and in vivo, and identified 3,3'-[(1,1'-Biphenyl)-4',4'-diyl)bis(azo)]bis[4-amino-1-naphthalenesulfonic acid] (congo red; CR; Zinc 03830554) as a high-affinity binder to the Pol gamma protein and potent inhibitor of the Pol gamma strand displacement and one-nucleotide incorporation DNA synthesis activities in vitro and in vivo. CR reduced the cell proliferation of MLH1 deficient HCT116 human colon cancer cells and suppressed HCT116 xenograft tumor growth whereas it did not affect the MLH1 proficient cell proliferation and xenograft tumor growth. CR caused mitochondrial dysfunction and cell death by inhibiting Pol gamma activity and oxidative mtDNA damage repair, increasing the production of reactive oxygen species and oxidative mtDNA damage in MLH1 deficient cells. This study suggests that the Pol gamma inhibitor, CR may be further evaluated for the MLH1 deficient cancers' therapy.
35657956	24	44	DNA polymerase gamma	Gene	5428
35657956	88	100	colon cancer	Disease	MESH:D015179
35657956	208	214	cancer	Disease	MESH:D009369
35657956	266	272	cancer	Disease	MESH:D009369
35657956	365	379	MutL homolog 1	Gene	4292
35657956	440	460	DNA polymerase gamma	Gene	5428
35657956	462	471	Pol gamma	Gene	5428
35657956	673	680	cancers	Disease	MESH:D009369
35657956	692	739	nonpolyposis colorectal and endometrial cancers	Disease	MESH:D016889
35657956	767	776	Pol gamma	Gene	5428
35657956	795	801	cancer	Disease	MESH:D009369
35657956	974	983	Pol gamma	Gene	5428
35657956	1032	1038	cancer	Disease	MESH:D009369
35657956	1069	1078	Pol gamma	Gene	5428
35657956	1136	1217	3,3'-[(1,1'-Biphenyl)-4',4'-diyl)bis(azo)]bis[4-amino-1-naphthalenesulfonic acid]	Chemical	-
35657956	1219	1228	congo red	Chemical	MESH:D003224
35657956	1230	1232	CR	Chemical	MESH:D002857
35657956	1234	1247	Zinc 03830554	Chemical	-
35657956	1282	1291	Pol gamma	Gene	5428
35657956	1328	1337	Pol gamma	Gene	5428
35657956	1362	1376	one-nucleotide	Chemical	-
35657956	1438	1440	CR	Chemical	MESH:D002857
35657956	1490	1496	HCT116	CellLine	CVCL:0291
35657956	1497	1502	human	Species	9606
35657956	1503	1515	colon cancer	Disease	MESH:D015179
35657956	1537	1543	HCT116	CellLine	CVCL:0291
35657956	1554	1559	tumor	Disease	MESH:D009369
35657956	1646	1651	tumor	Disease	MESH:D009369
35657956	1660	1662	CR	Chemical	MESH:D002857
35657956	1670	1695	mitochondrial dysfunction	Disease	MESH:D028361
35657956	1725	1734	Pol gamma	Gene	5428
35657956	1808	1831	reactive oxygen species	Chemical	MESH:D017382
35657956	1913	1922	Pol gamma	Gene	5428
35657956	1934	1936	CR	Chemical	MESH:D002857
35657956	Association	MESH:D015179	5428
35657956	Negative_Correlation	MESH:D002857	MESH:D015179
35657956	Negative_Correlation	MESH:D002857	5428
35657956	Positive_Correlation	MESH:D002857	MESH:D017382
35657956	Negative_Correlation	MESH:D002857	MESH:D009369
35657956	Negative_Correlation	MESH:D003224	5428
35657956	Positive_Correlation	MESH:D002857	MESH:D028361
35657956	Association	MESH:D028361	5428
35657956	Association	MESH:D009369	5428

